Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Launched by ROHAN DHARMAKUMAR · Oct 27, 2022
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring whether a medication called Deferiprone can help patients who have experienced a heart attack (specifically, a type known as STEMI) by reducing excess iron in the heart muscle where bleeding has occurred. The researchers are looking to find out if Deferiprone can improve recovery in patients who have had a heart attack that resulted in bleeding within the heart tissue.
To participate in this study, you need to be between 18 and 79 years old and have had a recent heart attack diagnosed according to specific guidelines. There are some important reasons why someone might not be eligible, such as a history of certain heart conditions or recent treatments. If you join the study, you will receive care according to the trial's design, and you will be closely monitored during the treatment. This research is in the early stages, and we hope it can lead to better treatments for heart attack patients in the future.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- • 1. Age ≥ 18 years
- • 2. Index Anterior wall STEMI
- • 3. Emergency coronary angiogram with primary PCI
- • Exclusion Criteria
- • 1. Prior history of MI / PCI / coronary artery bypass graft (CABG) within previous 1 year
- • 2. Patients with previous history of left ventricular ejection fraction (LVEF) \< 40%
- • 3. Use of investigational drugs or devices 30 days prior to randomization
- • 4. Known allergy or contra-indication to gadolinium/contrast agents
- • 5. eGFR \< 30 ml/kg/min
- • 6. Any contraindication against cardiac MRI (such as metal implants)
- • 7. Women who are pregnant or breastfeeding. Women of reproductive potential must have a negative pregnancy test prior to randomization
- • 8. Body weight \> 140 kg (or 309 lbs.)
- • 9. Absolute neutrophil count - ANC \< 1.5 k/cumm
- • 10. History of Chronic Liver Disease
- • 11. Elevated hepatic enzymes (BOTH ALT and AST) \> 2 times of upper normal limit
- • 12. Patients with iron storage disease (hemochromatosis, thalassemia) or who are already treated with iron chelators
- • 13. Any clinically significant abnormality identified prior to randomization that in the judgment of the Sponsor-Investigator or Delegate would preclude safe completion of the study or confound the anticipated benefit of deferiprone.
- • 14. Life expectancy of less than 1 year due to non-cardiac pathology
About Rohan Dharmakumar
Rohan Dharmakumar is a distinguished clinical trial sponsor dedicated to advancing medical research through innovative and rigorously designed studies. With a strong focus on cardiovascular health and metabolic diseases, Dharmakumar’s initiatives aim to bridge the gap between scientific discovery and clinical application. Leveraging a collaborative approach, the sponsor works closely with academic institutions, healthcare professionals, and regulatory bodies to ensure the integrity and efficacy of its trials. Committed to ethical standards and patient safety, Rohan Dharmakumar's efforts contribute significantly to the enhancement of therapeutic options and improved health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Indianapolis, Indiana, United States
Patients applied
Trial Officials
Rohan Dharmakumar, PhD
Principal Investigator
Krannert Cardiovascular Research Center
Keyur P Vora, MD FACP FACC
Principal Investigator
Krannert Cardiovascular Research Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials